TY - JOUR
T1 - A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier
AU - Shinto, Eiji
AU - Oki, Eiji
AU - Shimokawa, Mototsugu
AU - Yamaguchi, Shigeki
AU - Ishiguro, Megumi
AU - Morita, Masaru
AU - Kusumoto, Tetsuya
AU - Tomita, Naohiro
AU - Hashiguchi, Yojiro
AU - Tanaka, Masafumi
AU - Ohnuma, Shinobu
AU - Tada, Sachiyo
AU - Matsushima, Tomoko
AU - Hase, Kazuo
N1 - Funding Information:
Editorial support in the form of medical writing, assembling tables, creating high-resolution images based on authors’ detailed directions, collating author comments, copyediting, fact checking, and referencing was provided by Editage, Cactus Communications and the study was funded by Sysmex Corporation. Part of this manuscript was presented as an abstract (Abstract Number for Publication: 3526) at the recent 2018 ASCO Annual Meeting held in Chicago, II, USA, June 1–5, 2018.
Publisher Copyright:
© 2020
PY - 2020/8/1
Y1 - 2020/8/1
N2 - DNA microarrays, such as the consensus molecular subtype (CMS) classification using 600 genes, are used to predict cancer patient prognosis. We recently constructed a simple 55-gene classifier (55GC) system to risk stratify colon cancer (CC). Objective: Here, we validate the 55GC specifically for stage II CC and compare it with CMS categories. Methods: Tissue sections from 232 stage II CC patients who underwent curative surgery without adjuvant chemotherapy between 2009 and 2012 were subjected to DNA microarray analysis. Results: Based on the 55GC, patients were classified into microsatellite instability-like (27%), chromosomal instability-like (41%), and stromal (32%) subtypes with 5-year relapse-free survival (RFS) rates of 88.5, 83.3, and 71.2%, respectively (stromal vs. others: p = 0.0049). Multivariate analysis by Cox's proportional hazard model revealed that the stromal subtype, pT4, and the number of lymph nodes examined (<12) were independent poor prognostic factors. The overall concordance rate between 55GC and CMS was 72%, and 5-year RFS rates of patients with CMS1, CMS2, CMS3, and CMS4 cancers were 100, 85.5, 92.3, and 73.0%, respectively (p = 0.0113). Conclusions: We conclude that the 55GC is a useful and reproducible grading system for stage II CC recurrence risk stratification.
AB - DNA microarrays, such as the consensus molecular subtype (CMS) classification using 600 genes, are used to predict cancer patient prognosis. We recently constructed a simple 55-gene classifier (55GC) system to risk stratify colon cancer (CC). Objective: Here, we validate the 55GC specifically for stage II CC and compare it with CMS categories. Methods: Tissue sections from 232 stage II CC patients who underwent curative surgery without adjuvant chemotherapy between 2009 and 2012 were subjected to DNA microarray analysis. Results: Based on the 55GC, patients were classified into microsatellite instability-like (27%), chromosomal instability-like (41%), and stromal (32%) subtypes with 5-year relapse-free survival (RFS) rates of 88.5, 83.3, and 71.2%, respectively (stromal vs. others: p = 0.0049). Multivariate analysis by Cox's proportional hazard model revealed that the stromal subtype, pT4, and the number of lymph nodes examined (<12) were independent poor prognostic factors. The overall concordance rate between 55GC and CMS was 72%, and 5-year RFS rates of patients with CMS1, CMS2, CMS3, and CMS4 cancers were 100, 85.5, 92.3, and 73.0%, respectively (p = 0.0113). Conclusions: We conclude that the 55GC is a useful and reproducible grading system for stage II CC recurrence risk stratification.
UR - http://www.scopus.com/inward/record.url?scp=85083391583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083391583&partnerID=8YFLogxK
U2 - 10.1159/000506369
DO - 10.1159/000506369
M3 - Article
C2 - 32235113
AN - SCOPUS:85083391583
SN - 0030-2414
VL - 98
SP - 534
EP - 541
JO - Oncology
JF - Oncology
IS - 8
ER -
